JCR Pharmaceuticals Revises FY2024 Earnings Forecast Amid Financial Challenges

The latest update is out from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ).

JCR Pharmaceuticals has revised its full-year consolidated earnings forecast for FY2024, anticipating significant financial losses due to an unfinalized licensing agreement and increased costs in sales and R&D. The company expects an operating loss of 6 billion yen and a loss attributable to owners of 4.3 billion yen, as extraordinary income from a government subsidy will not be realized this fiscal year. These adjustments reflect challenges in JCR’s financial performance, impacting its market positioning and stakeholder expectations.

More about JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company focused on developing therapies for rare and genetic diseases. With a strong presence in Japan and expanding operations in the US, Europe, and Latin America, JCR is dedicated to improving patients’ lives through innovative research and development. The company offers approved treatments for conditions such as growth disorders, MPS II, Fabry disease, and more, while also working on investigational products for various rare diseases.

YTD Price Performance: -10.38%

Average Trading Volume: 604,538

Technical Sentiment Signal: Buy

Current Market Cap: Yen67.32B

See more insights into 4552 stock on TipRanks’ Stock Analysis page.